- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting CDK9 for Anti-Cancer Therapeutics
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 9, Pages 2181
Publisher
MDPI AG
Online
2021-05-02
DOI
10.3390/cancers13092181
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
- (2021) Sarah K. Madden et al. Molecular Cancer
- CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9
- (2021) Yanli Zhang et al. Cell Death & Disease
- Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
- (2020) Jonathan Chou et al. Cancer Discovery
- A kinase of many talents: non-neuronal functions of CDK5 in development and disease
- (2020) Samanta Sharma et al. Open Biology
- Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors
- (2020) Thomas Robert et al. Frontiers in Chemistry
- CDKI-73 Is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion
- (2020) Alexandra Sorvina et al. Cells
- Caspase-8: The double-edged sword
- (2020) Ranadip Mandal et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
- (2020) Sarah Diab et al. JOURNAL OF MEDICINAL CHEMISTRY
- CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
- (2020) Zheng Fan et al. Science Advances
- Inhibition of the Super Elongation Complex Suppresses Herpes Simplex Virus Immediate Early Gene Expression, Lytic Infection, and Reactivation from Latency
- (2020) Roberto Alfonso-Dunn et al. mBio
- CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas
- (2020) Matteo Cassandri et al. Frontiers in Pharmacology
- Bromodomain inhibitors a decade later: a promise unfulfilled?
- (2020) Monica M. Mita et al. BRITISH JOURNAL OF CANCER
- The role of caspase-8 in the tumor microenvironment of ovarian cancer
- (2020) Izabela Kostova et al. CANCER AND METASTASIS REVIEWS
- Targeting CDK9: A novel biomarker in�the�treatment of endometrial cancer
- (2020) Shasha He et al. ONCOLOGY REPORTS
- MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
- (2020) Arnold Bolomsky et al. Journal of Hematology & Oncology
- Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
- (2020) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Is CDK9 a promising target for both primary and metastatic osteosarcoma?
- (2019) Jiang-Jiang Qin EBioMedicine
- Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer
- (2019) Jinglu Wang et al. FASEB JOURNAL
- CDK16: the pick of the understudied PCTAIRE kinases
- (2019) Alison Axtman et al. NATURE REVIEWS DRUG DISCOVERY
- The complete structure of the human TFIIH core complex
- (2019) Basil J Greber et al. eLife
- A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
- (2019) Elijah W. Chen et al. Frontiers in Immunology
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
- (2019) Jing Zhang et al. Molecular Cancer
- AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.
- (2019) Justin Cidado et al. CLINICAL CANCER RESEARCH
- Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer
- (2019) Xin Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach
- (2019) Daniel J. Lee et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
- (2019) Clara Alcon et al. CLINICAL CANCER RESEARCH
- CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism
- (2018) Hongtao Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation
- (2018) Uri Mbonye et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CDK9 inhibitors in acute myeloid leukemia
- (2018) Silvia Boffo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeting MYC in multiple myeloma
- (2018) K. K. Jovanović et al. LEUKEMIA
- MYC protein expression is an important prognostic factor in acute myeloid leukemia
- (2018) Maro Ohanian et al. LEUKEMIA & LYMPHOMA
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- Born to run: control of transcription elongation by RNA polymerase II
- (2018) Fei Xavier Chen et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
- (2018) Daniel Gerlach et al. ONCOGENE
- Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia
- (2018) Joachim R. Göthert et al. Oncotarget
- Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor
- (2018) Beilei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- (2018) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.
- (2018) Jennifer Robinson Diamond et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.
- (2018) Simon Rule et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Brd4 for cancer therapy: inhibitors and degraders
- (2018) Yingchao Duan et al. MedChemComm
- Structural insights into the functional diversity of the CDK–cyclin family
- (2018) Daniel J. Wood et al. Open Biology
- Role of Androgen Receptor in Prostate Cancer: A Review
- (2018) Kazutoshi Fujita et al. World Journal of Mens Health
- Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy
- (2018) Kaiwei Liang et al. CELL
- The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
- (2018) Balbina García-Reyes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cyclin‐dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway
- (2018) Junfen Xu et al. IUBMB LIFE
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Structure of human TFIID and mechanism of TBP loading onto promoter DNA
- (2018) Avinash B. Patel et al. SCIENCE
- Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
- (2018) Esmée Braams et al. Oncotarget
- Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
- (2018) Hangzhan Ma et al. EBioMedicine
- CDK9: A key player in cancer and other diseases
- (2017) Lia Carolina Franco et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE
- (2017) Nikolas Ferreira dos Santos Paparidis et al. Molecular BioSystems
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- Transcription regulation by the Mediator complex
- (2017) Julie Soutourina NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
- (2017) Natalia Moreno et al. Oncotarget
- Combined venetoclax and alvocidib in acute myeloid leukemia
- (2017) James Bogenberger et al. Oncotarget
- MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
- (2017) Amanda C. Winters et al. Frontiers in Pediatrics
- A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
- (2017) D. Mahadevan et al. JOURNAL OF CLINICAL ONCOLOGY
- PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity
- (2017) Shinya Matsuda et al. Scientific Reports
- Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
- (2016) Shao Xie et al. ACTA PHARMACOLOGICA SINICA
- P-TEFb goes viral
- (2016) Justyna Zaborowska et al. BIOESSAYS
- Overview of CDK9 as a target in cancer research
- (2016) Fatima Morales et al. CELL CYCLE
- Targeting CDK9: a promising therapeutic opportunity in prostate cancer
- (2016) Muhammed H Rahaman et al. ENDOCRINE-RELATED CANCER
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
- (2016) Yogesh A. Sonawane et al. JOURNAL OF MEDICINAL CHEMISTRY
- The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
- (2016) Matthew D. Seftel et al. LEUKEMIA & LYMPHOMA
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb
- (2016) Alexandre J. C. Quaresma et al. NUCLEIC ACIDS RESEARCH
- Human CDK18 promotes replication stress signaling and genome stability
- (2016) Giancarlo Barone et al. NUCLEIC ACIDS RESEARCH
- Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
- (2016) Annelie Hellvard et al. Scientific Reports
- ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development
- (2015) Lekun Fang et al. CANCER CELL
- CDK9 and its repressor LARP7 modulate cardiomyocyte proliferation and response to injury in the zebrafish heart
- (2015) G. Matrone et al. JOURNAL OF CELL SCIENCE
- HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
- (2015) S G T Devaraj et al. LEUKEMIA
- Structural basis of transcription initiation by RNA polymerase II
- (2015) Sarah Sainsbury et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
- (2015) R Mandal et al. ONCOGENE
- COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer
- (2015) Shujun Gao et al. Oncotarget
- A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
- (2015) Elisabeth Walsby et al. Oncotarget
- ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34
- (2014) Mi Hee Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
- (2014) E X Chen et al. BRITISH JOURNAL OF CANCER
- Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation
- (2014) Shan Li et al. FEBS LETTERS
- Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263
- (2014) Gernot Polier et al. INTERNATIONAL JOURNAL OF CANCER
- A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
- (2014) T. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis
- (2014) Yves Matthess et al. Molecular Oncology
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
- (2014) Friederike Itzen et al. NUCLEIC ACIDS RESEARCH
- The structure and substrate specificity of human Cdk12/Cyclin K
- (2014) Christian A. Bösken et al. Nature Communications
- Regulation of CDK9 Activity by Phosphorylation and Dephosphorylation
- (2014) Sergei Nekhai et al. Biomed Research International
- RNA Polymerase II transcription elongation and Pol II CTD Ser2 phosphorylation
- (2014) Elizabeth A Bowman et al. Nucleus
- Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers
- (2013) Surojeet Sengupta et al. BREAST CANCER RESEARCH AND TREATMENT
- Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor
- (2013) T K Albert et al. BRITISH JOURNAL OF PHARMACOLOGY
- Stable Pausing by RNA Polymerase II Provides an Opportunity to Target and Integrate Regulatory Signals
- (2013) Telmo Henriques et al. MOLECULAR CELL
- pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner
- (2013) Ranadip Mandal et al. Molecular Oncology
- CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
- (2013) C Delehouzé et al. ONCOGENE
- Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook.f and Amoora rohituka (Roxb).Wight & Arn
- (2013) P. Mohana Kumara et al. PHYTOMEDICINE
- CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome
- (2013) V. J. Guen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural insights into transcription initiation by RNA polymerase II
- (2013) Sebastian Grünberg et al. TRENDS IN BIOCHEMICAL SCIENCES
- Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes
- (2013) Uri R. Mbonye et al. PLoS Pathogens
- HEXIM1, a New Player in the p53 Pathway
- (2013) Qiao Lew et al. Cancers
- RNA Polymerase II Elongation Control
- (2012) Qiang Zhou et al. Annual Review of Biochemistry
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- The cyclin K/Cdk12 complex
- (2012) Dalibor Blazek CELL CYCLE
- Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
- (2012) Vladimir Krystof et al. CURRENT PHARMACEUTICAL DESIGN
- Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation
- (2012) Shaoyong Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- mRNA Decapping Factors and the Exonuclease Xrn2 Function in Widespread Premature Termination of RNA Polymerase II Transcription
- (2012) Kris Brannan et al. MOLECULAR CELL
- TFIIH: when transcription met DNA repair
- (2012) Emmanuel Compe et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The super elongation complex (SEC) family in transcriptional control
- (2012) Zhuojuan Luo et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
- (2012) Stéphane Larochelle et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Cyclin K goes with Cdk12 and Cdk13
- (2012) Jiri Kohoutek et al. Cell Division
- Perspective: Expanding role of cyclin dependent kinases in cytokine inducible gene expression
- (2011) Allan R. Brasier CELL CYCLE
- Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma
- (2011) Christopher Abdullah et al. CELL CYCLE
- Two-pronged Binding with Bromodomain-containing Protein 4 Liberates Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein Complexes
- (2011) Sebastian Schröder et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5
- (2011) Fu-Ning Hsu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway
- (2011) Rajesh Ramakrishnan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Cyclin-Dependent Kinase 16/PCTAIRE Kinase 1 Is Activated by Cyclin Y and Is Essential for Spermatogenesis
- (2011) P. Mikolcevic et al. MOLECULAR AND CELLULAR BIOLOGY
- Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin
- (2011) N. He et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
- (2011) G Polier et al. Cell Death & Disease
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Cdk1/Cyclin B1 Controls Fas-Mediated Apoptosis by Regulating Caspase-8 Activity
- (2010) Y. Matthess et al. MOLECULAR AND CELLULAR BIOLOGY
- AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples
- (2010) Matthew S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation
- (2010) Vicki Gordon et al. MOLECULAR ENDOCRINOLOGY
- Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
- (2010) Kamil Paruch et al. ACS Medicinal Chemistry Letters
- SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- (2009) Andrew Conroy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
- (2009) Friederike Vollmuth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- A capping-independent function of MePCE in stabilizing 7SK snRNA and facilitating the assembly of 7SK snRNP
- (2009) Y. Xue et al. NUCLEIC ACIDS RESEARCH
- P-TEFb- the final frontier
- (2009) Jiri Kohoutek Cell Division
- The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
- (2008) Sonja Baumli et al. EMBO JOURNAL
- The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes
- (2008) Andreas Markert et al. EMBO REPORTS
- Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†
- (2008) Paul G. Wyatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bromodomain Protein Brd4 Regulates Human Immunodeficiency Virus Transcription through Phosphorylation of CDK9 at Threonine 29
- (2008) M. Zhou et al. JOURNAL OF VIROLOGY
- LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated
- (2008) B. J. Krueger et al. NUCLEIC ACIDS RESEARCH
- CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
- (2008) K Bettayeb et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started